Evidence map›Paper›PMID 24507464›Full record

ArticleParticle and fibre toxicology2014

Sub-chronic toxicity study in rats orally exposed to nanostructured silica.

Meike van der Zande, Rob J Vandebriel, Maria J Groot, Evelien Kramer, Zahira E Herrera Rivera, Kirsten Rasmussen, Jan S Ossenkoppele, Peter Tromp, Eric R Gremmer, Ruud J B Peters and 5 more

Open access · goldAbstract read
In one paragraph

Article in Particle and fibre toxicology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed, 2 pooled it
18.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 2 syntheses or guidelines pooled it, 199 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Toxicity evaluation of silica nanoparticles for delivery applications.Drug delivery and translational research · 2023
    Review
  11. Article
  12. Article
  13. Nanomedicine-Enabled/Augmented Cell Pyroptosis for Efficient Tumor Nanotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022
    Review
  14. Article
  15. Review
  16. Article
  17. Potential Toxic Effects of Exposure to Titanium Silicon Oxide Nanoparticles in Male Rats.International journal of environmental research and public health · 2022
    Article
  18. Review
  19. Review
  20. Article

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 2 countries.

Meike van der ZandeRIKILT - Wageningen University & Research Centre, 6700 AE Wageningen, The Netherlands. Meike.vanderzande@wur.nl.
Rob J Vandebriel
Maria J Groot
Evelien Kramer
Zahira E Herrera Rivera
Kirsten Rasmussen
Jan S Ossenkoppele
Peter Tromp
Eric R Gremmer
Ruud J B Peters
Peter J Hendriksen
Hans J P Marvin
Ron L A P Hoogenboom
Ad A C M Peijnenburg
Hans Bouwmeester
Wageningen University & Research · NLNational Institute for Public Health and the Environment · NLJoint Research Centre · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSynthetic Amorphous Silica (SAS) is commonly used in food and drugs. Recently, a consumer intake of silica from food was estimated at 9.4 mg/kg bw/day, of which 1.8 mg/kg bw/day was estimated to be in the nano-size range. Food products containing SAS have been shown to contain silica in the nanometer size range (i.e. 5-200 nm) up to 43% of the total silica content. Concerns have been raised about the possible adverse effects of chronic exposure to nanostructured silica.

methodsRats were orally exposed to 100, 1000 or 2500 mg/kg bw/day of SAS, or to 100, 500 or 1000 mg/kg bw/day of NM-202 (a representative nanostructured silica for OECD testing) for 28 days, or to the highest dose of SAS or NM-202 for 84 days.

resultsSAS and NM-202 were extensively characterized as pristine materials, but also in the feed matrix and gut content of the animals, and after in vitro digestion. The latter indicated that the intestinal content of the mid/high-dose groups had stronger gel-like properties than the low-dose groups, implying low gelation and high bioaccessibility of silica in the human intestine at realistic consumer exposure levels. Exposure to SAS or NM-202 did not result in clearly elevated tissue silica levels after 28-days of exposure. However, after 84-days of exposure to SAS, but not to NM-202, silica accumulated in the spleen. Biochemical and immunological markers in blood and isolated cells did not indicate toxicity, but histopathological analysis, showed an increased incidence of liver fibrosis after 84-days of exposure, which only reached significance in the NM-202 treated animals. This observation was accompanied by a moderate, but significant increase in the expression of fibrosis-related genes in liver samples.

conclusionsAlthough only few adverse effects were observed, additional studies are warranted to further evaluate the biological relevance of observed fibrosis in liver and possible accumulation of silica in the spleen in the NM-202 and SAS exposed animals respectively. In these studies, dose-effect relations should be studied at lower dosages, more representative of the current exposure of consumers, since only the highest dosages were used for the present 84-day exposure study.

Indexed as

AnimalsCytokinesElasticityInhalation ExposureJejunumLiverLymph NodesMaleMass SpectrometryNanostructuresParticle SizeRatsRats, Sprague-DawleyRNA, MessengerSilicon DioxideSpectrophotometry, InfraredCytokinesRNA, MessengerSilicon Dioxide

Identifiers

PMID24507464
PMCPMC3922429
OpenAlexW2121818758

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.